What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 18; and three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 26.

2. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising a HCVR that comprises an amino acid sequence set forth in SEQ ID NO:18.

3. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising a LCVR that comprises an amino acid sequence set forth in SEQ ID NO: 26.

4. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising a LCVR that comprises an amino acid sequence set forth in SEQ ID NO: 26; and a HCVR that comprises an amino acid sequence set forth in SEQ ID NO: 18.

5. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) a HCDR1 that comprises an amino acid sequence set forth in SEQ ID NO: 20;

(b) a HCDR2 that comprises an amino acid sequence set forth in SEQ ID NO: 22;

(c) a HCDR3 that comprises an amino acid sequence set forth in SEQ ID NO: 24;

(d) a LCDR1 that comprises an amino acid sequence set forth in SEQ ID NO: 28;

(e) a LCDR2 that comprises an amino acid sequence set forth in SEQ ID NO: 30; and

(f) a LCDR3 that comprises an amino acid sequence set forth in SEQ ID NO: 32.

6. The isolated antibody or antigen-binding fragment of claim 4 which is an antibody.

7. The isolated antibody of claim 6 which is a recombinant antibody.

8. The isolated antibody of claim 6 which is bispecific.

9. A pharmaceutical composition comprising the isolated antibody of claim 6 and a pharmaceutically acceptable carrier or diluent.

10. The pharmaceutical composition of claim 9 further comprising a second therapeutic agent.

11. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a HCVR or an LVCR or both of the antibody of claim 6.

12. A vector comprising the polynucleotide of claim 11.

13. An isolated cell comprising the vector of claim 12.

14. The pharmaceutical composition of claim 10 wherein the second therapeutic agent is an anti-viral drug.

15. The pharmaceutical composition of claim 10 wherein the second therapeutic agent is a neuraminidase inhibitor or an interferon.

16. The pharmaceutical composition of claim 10 wherein the second therapeutic agent is zidovudine, gangcyclovir, vidarabine, idoxuridine, trifluridine, foscarnet, acyclovir, ribavirin, amantadine, remantidine, saquinavir, indinavir, ritonavir, zanamivir, oseltamivir, laninamivir, peramivir or rimantadine.